Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Operations (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Cash from Operations over the past 16 years, most recently at 5347000.0 for Q2 2025.

For Q2 2025, Cash from Operations fell 38.65% year-over-year to 5347000.0; the TTM value through May 2025 reached 206000.0, down 180.16%, while the annual FY2025 figure was 206000.0, 180.16% down from the prior year.
Cash from Operations for Q2 2025 was 5347000.0 at Lifecore Biomedical, Inc. \De\, up from 1200000.0 in the prior quarter.
Over five years, Cash from Operations peaked at 8716000.0 in Q2 2024 and troughed at 17310000.0 in Q1 2022.
A 5-year average of 2331555.56 and a median of 1635000.0 in 2022 define the central range for Cash from Operations.
Biggest five-year swings in Cash from Operations: crashed 656.49% in 2023 and later skyrocketed 485.32% in 2024.
Year by year, Cash from Operations stood at 4810000.0 in 2021, then surged by 51.08% to 2353000.0 in 2022, then surged by 154.74% to 1288000.0 in 2023, then tumbled by 576.71% to 6140000.0 in 2024, then skyrocketed by 187.08% to 5347000.0 in 2025.
Business Quant data shows Cash from Operations for LFCR at 5347000.0 in Q2 2025, 1200000.0 in Q1 2025, and 6140000.0 in Q4 2024.